Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Deferred Revenue: 2022-2025

Historic Current Deferred Revenue for Taysha Gene Therapies (TSHA) over the last 3 years, with Sep 2025 value amounting to $5.5 million.

  • Taysha Gene Therapies' Current Deferred Revenue fell 53.39% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 53.39%. This contributed to the annual value of $9.8 million for FY2024, which is 45.87% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Current Deferred Revenue is $5.5 million, which was down 0.00% from $5.5 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Current Deferred Revenue registered a high of $33.6 million during Q4 2022, and its lowest value of $5.5 million during Q2 2025.
  • In the last 3 years, Taysha Gene Therapies' Current Deferred Revenue had a median value of $13.6 million in 2024 and averaged $14.0 million.
  • Data for Taysha Gene Therapies' Current Deferred Revenue shows a maximum YoY tumbled of 59.56% (in 2025) over the last 5 years.
  • Taysha Gene Therapies' Current Deferred Revenue (Quarterly) stood at $33.6 million in 2022, then plummeted by 46.04% to $18.1 million in 2023, then slumped by 45.87% to $9.8 million in 2024, then crashed by 53.39% to $5.5 million in 2025.
  • Its Current Deferred Revenue was $5.5 million in Q3 2025, compared to $5.5 million in Q2 2025 and $7.5 million in Q1 2025.